Posted by Michael Wonder on 29 Sep 2020
Australian patients to benefit from ongoing collaboration between peak medicine bodies
29 September 2020 - ACCC extends conditional authorisation to Medicines Australia and the Generic and Biosimilar Medicines Association
Australian patients, in particular those who urgently need medicines in their fight against COVID-19, are at the centre of a decision today by Australian Competition and Consumer Commission (ACCC) to allow the Medicines Australia and the Generic and Biosimilar Medicines Association to continue their collaboration.
The leadership of the two organisations today welcomed the decision by the ACCC to extend its conditional authorisation. This will enable the pharmaceutical sector to continue to work together on developing and implementing strategies that support the supply of essential medicines to all Australians.
